Aura Biosciences to Participate in Upcoming Investor Conferences
November 08 2023 - 6:00AM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that Elisabet de los Pinos, PhD, Chief Executive Officer,
will participate in the following upcoming investor
conferences:
- Jefferies London Healthcare Conference on Wednesday,
November 15, 2023. Presentation at 9:30 a.m. ET.
- 6th Annual Evercore ISI HealthCONx Conference on Wednesday,
November 29, 2023. Fireside Chat at 4:15 p.m. ET.
The live webcasts of the presentation and fireside chat will be
available on the “Investors & Media” page under the “Events
& Presentations” section of the Company’s website at
https://ir.aurabiosciences.com/events-and-presentations, where a
replay of the webcast will be archived for 90 days following the
presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing VDCs, a novel class of therapies, for the treatment of
multiple oncology indications. Aura’s lead VDC candidate,
belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like
particle conjugated with an anti-cancer agent. Bel-sar is designed
to selectively target and destroy cancer cells and activate the
immune system with the potential to create long-lasting, anti-tumor
immunity. Bel-sar is currently in development for ocular cancers,
and Aura has initiated activities for the global Phase 3 trial
evaluating first-line treatment of early-stage choroidal melanoma,
a vision- and life-threatening form of eye cancer where the
standard of care with radiotherapy leaves patients with severe
comorbidities, including significant vision loss. Aura plans to
pursue development of bel-sar across its ocular oncology franchise
including for the treatment of patients with choroidal metastasis.
In addition, leveraging Aura’s technology platform, Aura is
developing bel-sar more broadly across multiple cancers, including
in patients with non-muscle invasive and muscle invasive bladder
cancer. Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108003026/en/
Investors and Media: Alex Dasalla Head of Investor
Relations and Corporate Communications
adasalla@aurabiosciences.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2024 to May 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From May 2023 to May 2024